By Chris Wack
Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease.
The clinical-stage biopharmaceutical company said the once-daily oral blarcamesine significantly slowed clinical progression by 36.3% at 48 weeks.
The phase 2b study demonstrated a safety profile with no associated neuroimaging adverse events.
Anavex said oral blarcamesine could represent a novel treatment in early Alzheimer's disease and be complementary or alternative to injectable anti-beta amyloid drugs.
The stock hit its 52-week high of $14.44 on Dec. 26, and is up 88% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 15, 2025 13:50 ET (18:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.